-
1 week ago | 
hcplive.com | Connor Iapoce
Mavacamten (Camzyos) missed its dual primary endpoints in the Phase 3 ODYSSEY-HCM trial assessing the cardiac myosin inhibitor against placebo for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (HCM).
-
1 week ago | 
hcplive.com | Connor Iapoce
Initial results from the Phase 1b Heart-2 clinical trial evaluating VERVE-102 gene therapy showed promising efficacy for the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).1 Announced by Verve Therapeutics on April 14, 2025, a single infusion of the in vivo gene editing medicine achieved dose-dependent reductions in blood PCSK9 and low-density lipoprotein cholesterol (LDL-C), with a mean LDL-C reduction of ≥50% and a...
-
1 week ago | 
hcplive.com | Connor Iapoce
Preventive cardiology is undergoing a transformation, driven by new therapies, advanced diagnostics, and a broader understanding of cardiovascular risk. As the field moves beyond traditional approaches, the focus is shifting toward more personalized, proactive care.
-
1 week ago | 
hcplive.com | Connor Iapoce
The US Food and Drug Administration (FDA) has awarded Fast Track designation to VERVE-102 for the treatment of individuals with hyperlipidemia and high cardiovascular risk to lower low-density lipoprotein cholesterol (LDL-C) levels.1Announced by Verve Therapeutics on April 11, 2025, VERVE-102 is undergoing safety and tolerability assessment in the Phase 1b Heart-2 clinical trial for adults with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).
-
2 weeks ago | 
hcplive.com | Connor Iapoce
The US Food and Drug Administration (FDA) has granted clearance to the Dexcom G7 15-day continuous glucose monitoring (CGM) system for individuals aged 18 years and older with diabetes.1Announced by Dexcom on April 10, 2025, the G7 CGM now boasts the longest-lasting CGM system with 15.5 days of wear and best-in-class accuracy with a mean absolute relative difference (MARD) of 8.0%.
-
2 weeks ago | 
hcplive.com | Connor Iapoce
Ophthalmology in Q1 2025 saw pivotal advancements across the regulatory, clinical, and innovation landscapes. Updates from the US Food and Drug Administration (FDA) marked progress in treatment delivery, long-term disease management, and first-in-class approvals, while late-stage trial data signaled shifting paradigms for chronic retinal diseases and neuroprotective strategies.
-
2 weeks ago | 
hcplive.com | Connor Iapoce
The landscape of cardiovascular medicine continues to evolve rapidly, with Q1 2025 delivering significant regulatory, clinical, and strategic developments. Novel therapeutics, key trial milestones, and expert insights are reshaping how clinicians understand and manage cardiovascular risk, disease progression, and rare disorders.
-
2 weeks ago | 
hcplive.com | Connor Iapoce
Rivaroxaban achieved comparable efficacy and safety to warfarin in resolving left ventricular blood clots in patients hospitalized with myocardial infarction (MI) without displaying evidence of excess harm, including mortality and bleeding risks.1 The open-label, non-inferiority, randomized controlled RIVAWAR trial, presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, enrolled 261 patients in Pakistan to treatment with rivaroxaban or warfarin for three...
-
3 weeks ago | 
hcplive.com | Connor Iapoce
Late-breaking results from the Phase 3 ZENITH trial, presented at American College of Cardiology (ACC) 2025 Annual Scientific Sessions, showed sotatercept (WINREVAIR) significantly reduced the risk of major morbidity and mortality events among patients with pulmonary arterial hypertension (PAH).1 Announced by Merck, and published simultaneously in the New England Journal of Medicine, on March 31, 2025, sotatercept lowered the risk of a composite endpoint of all-cause mortality, lung...
-
3 weeks ago | 
hcplive.com | Connor Iapoce
Pulse oximeter estimates of blood oxygen saturation levels and traditional measurements of oxygen saturation in arterial blood significantly diverged by skin pigment in critically ill adults in the EquiOx study, according to new research presented at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions.1 These data from a large prospective real-world study showed an overall bias toward an underestimate of blood oxygen with pulse oximeters, while people with darker...
